Another thing: the company said they planned to request the FDA EOP2 B-OM meeting in late September. They did it today, Oct 10. That's about 2 weeks late.
The point is this: If those Aspire deal milestones (BTD and B deal) are off by similar margins, we might be hearing soon on them. BTD has an expiration date (60 days from submission, barring changes). A Brilacidin deal has no deadline but if the company was thinking it was possible to consummate by Sep 30, then maybe it is close to completion (just like the FDA meeting request).
(Note: Getting Prurisol results is a function of money, not time. We were apparently blind-sided by a trial bill or payment demand from the CRO, because there's no reason we would have made it a funding milestone otherwise.)
The two good pieces of news from yesterday: (1) we're getting P results, some day, because we can now pay the CRO (2) we can keep the lights on while negotiating the B deal. And, of course, we can finish the K pill, though we'd all prefer that and everything else to wait until our capital is much cheaper.
Market Data 
Markets 
AI
